Victor Joo, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina, Douglas Daoudlarian, Rita De Micheli, Menno Pruijm, Solange Peters, Roger Hullin, Olivier Gaide, Giuseppe Pantaleo, Michel Obeid
The application of mammalian target of rapamycin inhibition (mTORi) as primary prophylactic therapy to optimize T cell effector function while preserving allograft tolerance remains challenging. Here, we present a comprehensive two-step therapeutic approach in a male patient with metastatic cutaneous squamous cell carcinoma and heart transplantation followed with concomitant longitudinal analysis of systemic immunologic changes. In the first step, calcineurin inhibitor/ mycophenolic acid is replaced by the mTORi everolimus to achieve an improved effector T cell status with increased cytotoxic activity (perforin, granzyme), enhanced proliferation (Ki67) and upregulated activation markers (CD38, CD69)...
April 30, 2024: Nature Communications